Comparative Pharmacology
Head-to-head clinical analysis: AMRIX versus PARAFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMRIX versus PARAFON FORTE DSC.
AMRIX vs PARAFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Chlorzoxazone acts on the central nervous system (CNS) at the spinal cord level, possibly by depressing polysynaptic reflexes, producing skeletal muscle relaxation without affecting neuromuscular transmission.
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
Adults: 4 g (500 mg x 8 tablets) orally every 6-8 hours as needed; maximum 8 g (16 tablets) per 24 hours.
None Documented
None Documented
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
1-3 hours (terminal); clinically relevant for dosing intervals of 4-6 hours.
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
Primarily renal (85-95% as glucuronide conjugates and unchanged drug; <5% fecal).
Category C
Category C
Muscle Relaxant
Muscle Relaxant/Analgesic Combination